Biomerica Inc. | Cash Flow

Fiscal year is June-May. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
215.70
331.40
1,499.80
908.60
1,465.80
Depreciation, Depletion & Amortization
207.00
253.30
232.40
219.20
186.60
Other Funds
125.30
41.80
5.20
55.00
49.40
Funds from Operations
350.90
417.90
559.20
634.30
1,198.80
Changes in Working Capital
511.30
12.50
350.40
88.50
24.60
Net Operating Cash Flow
862.30
405.50
208.80
722.90
1,174.20
Capital Expenditures
283.70
24.70
95.20
96.10
130.30
Sale of Fixed Assets & Businesses
1.20
1.90
-
-
-
Net Investing Cash Flow
282.50
22.80
95.20
96.10
130.30
Net Financing Cash Flow
185.30
9.60
1,105.90
157.70
1,294.30
Net Change in Cash
960.70
420.80
800.60
663.50
20.60
Free Cash Flow
999.50
416.00
300.30
818.90
1,304.60
Deferred Taxes & Investment Tax Credit
217.00
298.00
703.00
-
31.00
Change in Capital Stock
185.30
9.60
1,105.90
157.70
1,294.30
Exchange Rate Effect
1.10
2.10
1.30
2.20
10.30

About Biomerica

View Profile
Address
17571 Von Karman Avenue
Irvine California 92614
United States
Employees -
Website http://www.biomerica.com
Updated 07/08/2019
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign.